Equities research analysts at StockNews.com started coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a report released on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.
Cyclacel Pharmaceuticals Stock Performance
Shares of NASDAQ:CYCC opened at $2.65 on Thursday. Cyclacel Pharmaceuticals has a fifty-two week low of $1.30 and a fifty-two week high of $13.20. The business has a 50-day simple moving average of $2.21 and a two-hundred day simple moving average of $3.69. The firm has a market cap of $3.50 million, a price-to-earnings ratio of -0.10 and a beta of 0.54.
Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) last issued its earnings results on Tuesday, March 19th. The biotechnology company reported ($6.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.35) by $0.12. The business had revenue of $0.03 million during the quarter. As a group, research analysts predict that Cyclacel Pharmaceuticals will post -18.7 earnings per share for the current year.
Cyclacel Pharmaceuticals Company Profile
Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.
Recommended Stories
- Five stocks we like better than Cyclacel Pharmaceuticals
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- AMD is Down 35%. Now is the Time to Buy the Dip
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Amazon Stands Tall: New Highs Are in Sight
- Stock Splits, Do They Really Impact Investors?
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.